<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186177">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670111</url>
  </required_header>
  <id_info>
    <org_study_id>RESET</org_study_id>
    <nct_id>NCT00670111</nct_id>
  </id_info>
  <brief_title>Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction</brief_title>
  <acronym>RESET</acronym>
  <official_title>Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at how pacing your heart may assist your daily activities and how you
      are feeling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESET is a multicenter trial that will assess the effect of pacing in heart failure patients
      with a normal ejection fraction (or diastolic heart failure). The purpose of the RESET study
      is to evaluate the effect of pacing on exercise capacity and quality of life in this heart
      failure population.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in enrollment
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak VO2</measure>
    <time_frame>1 month, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two experimental and/or intervention groups under 1 arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insignia Plus / Ultra (Guidant/Boston Scientific)</intervention_name>
    <description>Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Guidant or Boston Scientific implantable pacemakers</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are in sinus rhythm

          -  Patients who are on stable medical therapy

          -  Patients who exhibit signs and symptoms of heart failure, NYHA Class II or III

          -  Patients who have experienced a hospitalization for decompensated heart failure;
             treatment for pulmonary congestion or volume overload; chronic treatment with a loop
             diuretic; or a BNP &gt; 125 ng/l.

          -  Left ventricular ejection fraction â‰¥ 50%

        Exclusion Criteria:

          -  Patients with persistent atrial fibrillation or atrial flutter

          -  Patients who are in complete heart block

          -  Patients who have experienced a recent MI or have unstable angina or require cardiac
             surgery or other procedures

          -  Patients who have severe heart valve disease or valve replacement

          -  Patients with a contraindication for a pacemaker system

          -  Patients who have a neuromuscular, orthopedic or other non-cardiac condition that
             prevents patient from exercise testing

          -  Patients who have infiltrative or hypertrophic cardiomyopathy

          -  Patients who have known severe pulmonary disease

          -  Patients with uncontrolled diabetes or blood pressure (SBP &gt; 160 mmHg or DBP &gt; 95
             mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Kass, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Associates of Northeast Arkansas</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler CV Consultants - Trinity Mother Frances</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kass DA, Kitzman DW, Alvarez GE. The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. J Card Fail. 2010 Jan;16(1):17-24. doi: 10.1016/j.cardfail.2009.08.008. Epub 2009 Oct 7.</citation>
    <PMID>20123314</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 8, 2011</lastchanged_date>
  <firstreceived_date>April 23, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Douglas Daum Ph.D. / Director, Therapy Research</name_title>
    <organization>Boston Scientific Cardiac Rhythm Management</organization>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>ejection fraction</keyword>
  <keyword>Heart failure normal ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
